Barclays PLC Has $1.70 Million Stock Position in Applied Therapeutics, Inc. (NASDAQ:APLT)

Barclays PLC boosted its stake in shares of Applied Therapeutics, Inc. (NASDAQ:APLT) by 186.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 200,012 shares of the company’s stock after acquiring an additional 130,102 shares during the quarter. Barclays PLC owned approximately 0.17% of Applied Therapeutics worth $1,702,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in APLT. Bank of New York Mellon Corp acquired a new position in shares of Applied Therapeutics during the second quarter worth approximately $1,325,000. Principal Financial Group Inc. acquired a new position in Applied Therapeutics during the 2nd quarter worth $54,000. Rhumbline Advisers boosted its position in Applied Therapeutics by 24,513.1% in the 2nd quarter. Rhumbline Advisers now owns 133,895 shares of the company’s stock valued at $625,000 after buying an additional 133,351 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Applied Therapeutics in the 2nd quarter valued at $54,000. Finally, Sei Investments Co. acquired a new stake in shares of Applied Therapeutics in the 2nd quarter valued at $535,000. Institutional investors and hedge funds own 98.31% of the company’s stock.

Wall Street Analyst Weigh In

APLT has been the topic of several research reports. Citigroup cut their price target on Applied Therapeutics from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 29th. Leerink Partners upped their target price on shares of Applied Therapeutics from $11.00 to $14.00 and gave the company an “outperform” rating in a research report on Thursday, September 19th. Robert W. Baird lowered their price target on shares of Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating for the company in a research report on Friday, November 29th. William Blair downgraded shares of Applied Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, December 23rd. Finally, Royal Bank of Canada reduced their price objective on shares of Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating on the stock in a research note on Friday, December 20th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $6.10.

Applied Therapeutics Price Performance

Shares of APLT stock opened at $0.68 on Friday. The stock has a market cap of $79.02 million, a PE ratio of -0.42 and a beta of 1.83. The stock has a 50-day moving average of $4.22 and a 200-day moving average of $5.73. Applied Therapeutics, Inc. has a one year low of $0.65 and a one year high of $10.62.

Applied Therapeutics Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.